| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Qualification | |
| Date Qualified: | March 10, 2025 4:00 P.M. |
| Form: | 1-A |
| CIK: | 0001468492 |
| Company Name: | HeartSciences Inc. |
| File Number: | 024-12572 |
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Qualification | |
| Date Qualified: | March 10, 2025 4:00 P.M. |
| Form: | 1-A |
| CIK: | 0001468492 |
| Company Name: | HeartSciences Inc. |
| File Number: | 024-12572 |
Save time and jump to the most important pieces.
Southlake, TX, May 29, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (NASDAQ:HSCS, HSCSW)) ("HeartSciences" or the "Company"), an artificial intelligence ("AI")-powered medical technology company focused on transforming ECGs/EKGs to enable earlier detection of heart disease, today announced the signing of its first commercial customer for the MyoVista Insights™ platform: Westcliffe Health Innovations, based in the United Kingdom. This milestone follows the recent launch of MyoVista Insights and the initiation of an early adopter program for reference sites earlier this month. Westcliffe Health Innovations provides cardiology services to the U.K. National Health Service (NHS) in the Bradfor
MIAMI, May 21, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 82nd Emerging Growth Conference on May 21 & 22, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 – Presenting Today, May 21, 2025 8:45Virtual Lobby opens.Register for the Conference. If you already registered, go ba
Southlake, TX, May 20, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (NASDAQ:HSCS) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that Chief Executive Officer Andrew Simpson will deliver a live presentation and participate in a Q&A session at the Emerging Growth Conference 82. Event Details: Date: Wednesday, May 21, 2025 Time: 10:15 AM EDT | 7:15 AM PDT Format: Virtual presentation with live Q&A Registration To attend this live, interactive online event, please register though: Emerging Growth Conference 82 This event prov
Southlake, TX, May 07, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (NASDAQ:HSCS) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the appointment of Dr. Girish Nadkarni, MD, Dr. Joshua Lampert, MD, and Dr. Akhil Vaid, MBBS, to its Scientific Advisory Board. These appointments underscore HeartSciences' commitment to advancing and transforming data-driven AI-ECG technology. "We are honored to welcome Dr. Girish Nadkarni, Dr. Joshua Lampert, and Dr. Akhil Vaid to our Scientific Advisory Board," said Andrew Simpson, CEO of HeartScien
Southlake, TX, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS, HSCSW))) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the appointment of Dr. Partho P. Sengupta, MD, MBBS, FACC, to its Scientific Advisory Board. "Dr. Sengupta has been an author on multiple peer reviewed AI-ECG publications using the Company's technology and we are delighted to have someone of his caliber join our growing Scientific Advisory Board," said Andrew Simpson, CEO of HeartSciences. "Dr. Sengupta has
Southlake, TX, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS, HSCSW))) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the appointment of Jordan B. Strom M.D., M.Sc., to its Scientific Advisory Board. "Dr. Strom has been assisting us in recent interactions with the FDA and we are delighted to welcome him to our Scientific Advisory Board as we prepare for FDA submission of our MyoVista device and cloud platform, in addition to algorithms licensed from the Icahn School of Medi
4 - HeartSciences Inc. (0001468492) (Issuer)
4 - HeartSciences Inc. (0001468492) (Issuer)
4 - HeartSciences Inc. (0001468492) (Issuer)
SC 13G - Heart Test Laboratories, Inc. (0001468492) (Subject)
SC 13G - Heart Test Laboratories, Inc. (0001468492) (Subject)
SC 13D - Heart Test Laboratories, Inc. (0001468492) (Subject)
Entered into Transformative Agreements with Icahn Mount Sinai Filed FDA Pre-Submission Request to Change to 510(k) Submission from De Novo following Issuance of New Classification for AI ECG by FDA To host conference call on Wednesday, October 25, 2023 Southlake, TX, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS, HSCSW))) ("HeartSciences" or the "Company"), an AI-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced a conference call to update investors on recent key achievements and positive developments. The conference call will be host
8-K - HeartSciences Inc. (0001468492) (Filer)
8-K - HeartSciences Inc. (0001468492) (Filer)
253G2 - HeartSciences Inc. (0001468492) (Filer)